Drug Approval | July 09, 2024
Olverembatinib approved for commercialization in Macau China
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Ibara will drive AI-powered clinical research innovation
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Subscribe To Our Newsletter & Stay Updated
